AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1428380 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 49
Study 3930720 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HC)
Number of subjects: 72
Study 3930720 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sodium thiomalate (GSTM)
Number of subjects: 72
Study 3930720 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine (PEN)
Number of subjects: 72
Study 31383537 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-fork-shaped miniplate
Number of subjects: 30
Study 31383537 — intervention group
Group type: COMPARATOR
Intervention: Conventional miniplate
Number of subjects: 30
Study 30043572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal‐jejunum nutrient canal placement using clamping pliers under gastroscope guidance
Number of subjects: 90
Study 30043572 — intervention group
Group type: COMPARATOR
Intervention: Intranasal‐jejunum nutrient canal placement using guide wire under gastroscope guidance
Number of subjects: 90
Study 27575565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI) at 6.0°C ± 0.5°C for 19 minutes
Number of subjects: 8
Study 27575565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 8
Study 24788875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobic (original product) 4 x 7.5 mg tablets
Number of subjects: 20
Study 24788875 — intervention group
Group type: COMPARATOR
Intervention: Melocam (generic product) 4 x 7.5 mg tablets
Number of subjects: 20
Study 23110267 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream (pain group)
Number of subjects: 26
Study 23110267 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (control group)
Number of subjects: 26
Study 20210618 — intervention group
Group type: EXPERIMENTAL
Intervention: HYR (hydrated, race trial)
Number of subjects: 17
Study 20210618 — intervention group
Group type: EXPERIMENTAL
Intervention: DYR (dehydrated, race trial)
Number of subjects: 17
Study 20210618 — intervention group
Group type: EXPERIMENTAL
Intervention: HYS (hydrated, submaximal trial)
Number of subjects: 17
Study 20210618 — intervention group
Group type: EXPERIMENTAL
Intervention: DYS (dehydrated, submaximal trial)
Number of subjects: 17
Study 18450339 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in phase II prophylactic HIV vaccine trials
Number of subjects: 0
Study 18450339 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruiting strategies
Number of subjects: 0
Study 18450339 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment effectiveness
Number of subjects: 0
Study 18450339 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment methods
Number of subjects: 0
Study 15657223 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg thrice daily)
Number of subjects: 61
Study 15657223 — intervention group
Group type: COMPARATOR
Intervention: Control (usual drug treatment)
Number of subjects: 61
Study 12819912 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 25 mg/m² (Epi25) on a weekly intravenous regimen
Number of subjects: 79
Study 12819912 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin 100 mg/m² (Epi100) on a 4-weekly regimen
Number of subjects: 79
Study 10619812 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine solution
Number of subjects: 156
Study 10619812 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 156
Study 8780333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg)
Number of subjects: 70
Study 8780333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 1738173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins A, C, and E supplementation for 6 months
Number of subjects: 20
Study 1738173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6229707 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 20
Study 6229707 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 20
Study 29813074 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring for 12 weeks (Group A)
Number of subjects: 170
Study 29813074 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring for 12 weeks (Group B)
Number of subjects: 170
Study 29813074 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal ring (both groups)
Number of subjects: 170
Study 29813074 — intervention group
Group type: COMPARATOR
Intervention: Screening for STIs
Number of subjects: 170
Study 29813074 — intervention group
Group type: COMPARATOR
Intervention: Testing for HIV
Number of subjects: 170
Study 28381653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on learning with a bench model simulator
Number of subjects: 86
Study 28381653 — intervention group
Group type: COMPARATOR
Intervention: Video-learning using an instructional video
Number of subjects: 86
Study 25701454 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib titration (5 mg twice daily during lead-in, followed by stepwise dose increases)
Number of subjects: 0
Study 25701454 — intervention group
Group type: COMPARATOR
Intervention: Placebo titration
Number of subjects: 0
Study 25701454 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib titration
Number of subjects: 0
Study 24004988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV testing (finger prick)
Number of subjects: 370
Study 24004988 — intervention group
Group type: COMPARATOR
Intervention: Conventional HIV serology (venepuncture)
Number of subjects: 370
Study 21959312 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 271
Study 21959312 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 271
Study 18252692 — intervention group
Group type: EXPERIMENTAL
Intervention: azithromycin-ER (2 g single oral dose)
Number of subjects: 64
Study 18252692 — intervention group
Group type: COMPARATOR
Intervention: azithromycin-IR (500 mg single oral dose)
Number of subjects: 64
Study 16647327 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline leisure physical activity (PAL)
Number of subjects: 274
Study 16647327 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure PAL at 1 year
Number of subjects: 274
Study 16647327 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure PAL at end of study (2 to 3 years)
Number of subjects: 274
Study 12807332 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate operation
Number of subjects: 209
Study 12807332 — intervention group
Group type: COMPARATOR
Intervention: 1 year waiting with orthoses
Number of subjects: 209
Study 12807332 — intervention group
Group type: COMPARATOR
Intervention: 1 year waiting without orthoses
Number of subjects: 209
Study 12807332 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 209
Study 10824377 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology
Number of subjects: 203
Study 10824377 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 203
Study 8925582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine hydrochloride (5.6 to 12.6 g/d)
Number of subjects: 15
Study 8925582 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo capsules
Number of subjects: 15
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) at doses of 10, 20, or 40 mg/kg administered by 30-minute drip infusion.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) at doses of 10 to 20 mg/kg/once, 2 to 3 times a day, maximum dose 173 mg/kg/day q.i.d.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with purulent meningitis.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with septicemia.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with pneumonia.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) in patients with UTI.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Staphylococcus aureus.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Streptococcus pneumoniae.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Gram-positive bacteria.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Gram-negative bacteria.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Haemophilus influenzae.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Pseudomonas aeruginosa.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Escherichia coli.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment for Klebsiella pneumoniae.
Number of subjects: 389
Study 1507401 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) treatment in cases with previous unsuccessful antibiotic therapies.
Number of subjects: 389
Study 6377899 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 200
Study 6377899 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 30461521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepean Dyspepsia Index (NDI) 25-item form
Number of subjects: 289
Study 30461521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepean Dyspepsia Index (NDI) 10-item short form
Number of subjects: 289
Study 30461521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepean Dyspepsia Index (NDI)
Number of subjects: 289
Study 30461521 — intervention group
Group type: EXPERIMENTAL
Intervention: External instruments for convergent validity
Number of subjects: 289
Study 29527759 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal (protein and fat consumed 15 minutes prior to carbohydrates)
Number of subjects: 20
Study 29527759 — intervention group
Group type: COMPARATOR
Intervention: Standard meal (all macronutrients consumed together)
Number of subjects: 20
Study 26517949 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Pacing
Number of subjects: 145
Study 23225026 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human epidermal growth factor (rhEGF) oral spray
Number of subjects: 58
Study 23225026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 23028263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF) 46 g daily for 4 months
Number of subjects: 1038
Study 19210513 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg
Number of subjects: 1819
Study 19210513 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 1819
Study 19210513 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1819
Study 17761356 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% minoxidil topical foam (MTF)
Number of subjects: 352
Study 17761356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 15090413 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical latanoprost 0.005% once daily for an average duration of 11 months
Number of subjects: 76
Study 15090413 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 76
Study 11795452 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave treatment (maxillary denture microwaved for one minute at 850 Watts, repeated three times)
Number of subjects: 34
Study 11795452 — intervention group
Group type: COMPARATOR
Intervention: Control (denture soak treatment in 0.2% chlorhexidine digluconate solution overnight for 14 days)
Number of subjects: 34
Study 11795452 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave treatment
Number of subjects: 34
Study 11795452 — intervention group
Group type: COMPARATOR
Intervention: Control (denture soak treatment)
Number of subjects: 34
Study 9513865 — intervention group
Group type: EXPERIMENTAL
Intervention: Five isometric exercises (medial tibial rotation, knee extension combined, knee extension alone, hip adduction, hip adduction with knee extension)
Number of subjects: 27
Study 9513865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFPS)
Number of subjects: 27
Study 8743519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (N)
Number of subjects: 28
Study 8743519 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 28
Study 2316885 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming system
Number of subjects: 30
Study 2316885 — intervention group
Group type: COMPARATOR
Intervention: Cotton blankets warmed to 37.0 degrees C
Number of subjects: 30
Study 488520 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 2400 mg daily
Number of subjects: 26
Study 488520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 26
Study 30551813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided L5-S1 epidural catheter placement
Number of subjects: 100
Study 30551813 — intervention group
Group type: COMPARATOR
Intervention: Non-ultrasound-guided higher lumbar interspace placement
Number of subjects: 100
Study 25004240 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable appliance with protruding springs
Number of subjects: 64
Study 25004240 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliance with multibrackets
Number of subjects: 64
Study 23220118 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 days of disuse (knee brace)
Number of subjects: 22
Study 21806694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (placebo pill)
Number of subjects: 154
Study 21806694 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo pill)
Number of subjects: 154
Study 19338543 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A injections (200 U or 100 U) followed by hydrodistention (HD)
Number of subjects: 67
Study 19338543 — intervention group
Group type: COMPARATOR
Intervention: Hydrodistention (HD) alone
Number of subjects: 67
Study 16688845 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of nasogastric tube and early oral feeding (experimental group, n=161)
Number of subjects: 316
Study 16688845 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=155)
Number of subjects: 316
Study 15483215 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity management intervention based on the Transtheoretical Model
Number of subjects: 329
Study 15483215 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 329
Study 11775047 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Ginkgo biloba (EGb) plus haloperidol (0.25 mg/kg/day)
Number of subjects: 109
Study 11775047 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus haloperidol (0.25 mg/kg/day)
Number of subjects: 109
Study 9375319 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program on a cycle ergometer
Number of subjects: 9
Study 1554114 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 1554114 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 20
Study 3878103 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Diprivan)
Number of subjects: 120
Study 3878103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine before propofol injection
Number of subjects: 120
Study 3878103 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 120
Study 31144488 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible ureteroscopy with ureteral access sheath (UAS)
Number of subjects: 131
Study 31144488 — intervention group
Group type: COMPARATOR
Intervention: Flexible ureteroscopy without ureteral access sheath (UAS)
Number of subjects: 131
Study 29496509 — intervention group
Group type: EXPERIMENTAL
Intervention: FT + NMES
Number of subjects: 16
Study 29496509 — intervention group
Group type: EXPERIMENTAL
Intervention: FT
Number of subjects: 16
Study 29496509 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAINING
Number of subjects: 16
Study 29496509 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 16
Study 26670679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodimed (protein shakes)
Number of subjects: 212
Study 26670679 — intervention group
Group type: COMPARATOR
Intervention: Standard diet using ordinary products
Number of subjects: 212
Study 25140908 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and home-based pedometer walking program
Number of subjects: 84
Study 25140908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 25140908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 84
Study 22241354 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (APR) administered with conventional antiemetic therapy
Number of subjects: 20
Study 22241354 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiemetic therapy (serotonin receptor antagonist and dexamethasone)
Number of subjects: 20
Study 20424852 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil suspended with 0.2 mg/ml aspirin (AS SiO)
Number of subjects: 29
Study 20424852 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil (control group)
Number of subjects: 29
Study 18065575 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 g alginate-pectin beverage
Number of subjects: 29
Study 18065575 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g alginate-pectin beverage
Number of subjects: 29
Study 18065575 — intervention group
Group type: COMPARATOR
Intervention: Control (no fiber)
Number of subjects: 29
Study 16097638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux scintigraphy using the knee-chest position
Number of subjects: 37
Study 16097638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux scintigraphy in the supine position
Number of subjects: 37
Study 16097638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux scintigraphy
Number of subjects: 37
Study 12399698 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) varnish treatment after professional tooth cleaning in mothers with high salivary MS counts
Number of subjects: 44
Study 12399698 — intervention group
Group type: COMPARATOR
Intervention: Control group of untreated mother-child pairs with high maternal salivary MS levels
Number of subjects: 44
Study 12399698 — intervention group
Group type: COMPARATOR
Intervention: Negative control group of mother-child pairs with low maternal salivary MS levels
Number of subjects: 44
Study 10451517 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA)
Number of subjects: 3691
Study 10451517 — intervention group
Group type: COMPARATOR
Intervention: Mid-trimester amniocentesis (MA)
Number of subjects: 3691
Study 10451517 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal hypertension
Number of subjects: 3691
Study 7594663 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐OMP (Hib polysaccharide conjugated with Neisseria meningitidis group B outer membrane protein complex)
Number of subjects: 0
Study 7594663 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP‐T (Hib polysaccharide‐tetanus toxoid conjugate)
Number of subjects: 0
Study 7594663 — intervention group
Group type: COMPARATOR
Intervention: Three doses of PRP‐OMP or PRP‐T at 4, 6, and 14 months
Number of subjects: 0
Study 2124027 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 15
Study 2124027 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study 2124027 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 (0.5 mg daily for 6‐14 days)
Number of subjects: 15
Study 2124027 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (60‐120 micrograms for 6‐8 days)
Number of subjects: 15
Study 7004624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CMFT)
Number of subjects: 318
Study 7004624 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 318
Study 7004624 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor-positive tumors (ER+)
Number of subjects: 318
Study 7004624 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor-negative tumors (ER-)
Number of subjects: 318
Study 31778314 — intervention group
Group type: EXPERIMENTAL
Intervention: CT perfusion imaging (CTPI)
Number of subjects: 33
Study 31159856 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance antidepressants (citalopram, sertraline, fluoxetine, mirtazapine)
Number of subjects: 0
Study 31159856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27686717 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week home-based rehabilitation (HBR) intervention
Number of subjects: 0
Study 27686717 — intervention group
Group type: COMPARATOR
Intervention: Standard of care plus written health advice (Control)
Number of subjects: 0
Study 25885697 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery MANTRA (6-week self-care intervention supplemented by peer mentorship)
Number of subjects: 0
Study 24018733 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 10 min)
Number of subjects: 12
Study 24018733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1.5 mA, 10 min)
Number of subjects: 12
Study 24018733 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (10 min)
Number of subjects: 12
Study 21900088 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC) 50 IU/kg
Number of subjects: 12
Study 21900088 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12